Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 12/20 | 0.72 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.72 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.64 |
| ▸ | MC3R | P41968 | 1/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.64 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16120984 | 0.89 | ADORA2B (0.81) | ADORA2BADORA2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL16558001 | 0.89 | ADORA2B (0.70) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL8443037 | 0.88 | ADORA2B (0.77) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL19533057 | 0.88 | ADORA2B (0.73) | ADORA2BADORA2ALMNAMAPTSMN1; SMN2 | |
| Hexanal SCHEMBL27324985 | 0.87 | ADORA2B (0.61) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL515570 | 0.87 | PDE4A (0.83) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL22471417 | 0.87 | ADORA2B (0.68) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL19370573 | 0.86 | ADORA2B (0.71) | ADORA2BADORA2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL16120979 | 0.86 | ADORA2B (0.85) | ADORA2BADORA2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL16120975 | 0.86 | ADORA2B (0.88) | ADORA2BADORA2ALMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119812357-A | Membrane electrode of oxyhydrogen fuel cell and oxyhydrogen fuel cell comprising same | 北京大学 | 2025-04-11 | — | — | CN | claimed |
| CN-117919253-A | Application of xanthine compound in preparation of medicines for activating primordial follicles | 华南理工大学 | 2024-04-26 | — | — | CN | claimed |
| US-20200062782-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2020-02-27 | — | — | US | claimed |
| WO-2018045464-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2018-03-15 | — | — | WO | claimed |
| US-20260083743-A1 | NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF | WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY (CN) | 2026-03-26 | — | — | US | disclosed |
| US-20250386846-A1 | Food Compositions Including Aragonite | NANT HOLDINGS IP LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12419336-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250194654-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2025-06-19 | — | — | US | disclosed |
| US-12310392-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119812357-A | Membrane electrode of oxyhydrogen fuel cell and oxyhydrogen fuel cell comprising same | 北京大学 | 2025-04-11 | — | — | CN | disclosed |
| US-20240381918-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2024-11-21 | — | — | US | disclosed |
| CN-115850279-B | Theophylline derived spontaneous combustion ionic salt and preparation method thereof | 哈尔滨工业大学（深圳） | 2024-11-15 | — | — | CN | disclosed |
| WO-2001093832-A2 | AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED DOSAGE REQUIREMENTS FOR EFFICACIOUS DELIVERY | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093833-A2 | KITS AND METHODS FOR OPTIMIZING THE EFFICACY OF CHONDROPROTECTIVE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001005253-A1 | COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| CN-1143115-A | Method for producing 3-methyl-7-alkyl-yellow purine micro-organism | AMANO PHARMA CO LTD (JP) | 1997-02-19 | — | — | CN | disclosed |
| US-5550041-A | PRODUCING 3-METHYL-7-ALKYLXANTHINE BY CULTIVATING PSEUDOMONAS TRANSFORMED TO PRODUCE CAFFEINE DEMETHYLASE IN NUTRIENT MEDIUM CONTAINING 1,3-DIMETHYL-7-ALKYLXANTHINE | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-27 | — | — | US | disclosed |
| CN-1088259-A | DNA fragment containing caffeine demethylase gene and microbial process for producing 3-methyl-7-alkylxanthine | AMANO PHARMA CO LTD (JP) | 1994-06-22 | — | — | CN | disclosed |
| CN-1010347-B | Method for improving ammonia development rate of diazo blueprint paper | STATE CHANGSH CHEMICAL PHOTOGR (CN) | 1990-11-07 | — | — | CN | disclosed |
| CN-1030828-A | Improve the method for ammonia developing rate of heavy-nitrogen printing paper | STATE OWNED CHANGSHA CHEMICAL (CN) | 1989-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062782-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | SNCA, PARK7, SYNJ2 | ADORA2B 2511/4885ADORA2A 2007/4885PDE4A 3046/4885 |
| US-20260083743-A1 | NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF | SLC5A1, PC, LDHA | ADORA2B 102/4885ADORA2A 314/4885PDE4A 2742/4885 |
| US-20250386846-A1 | Food Compositions Including Aragonite | PLCG2, PLCG1, PLCB3 | ADORA2B 1369/4885ADORA2A 2335/4885PDE4A 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.